North China Pharmaceutical Company Ltd.

Shanghai Stock Exchange 600812.SS

North China Pharmaceutical Company Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 1.85

North China Pharmaceutical Company Ltd. Debt to Equity Ratio is 1.85 for the year ending December 31, 2023, a -11.12% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

North China Pharmaceutical Company Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 2.08, a -7.92% change year over year.
North China Pharmaceutical Company Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 2.26, a 8.34% change year over year.
North China Pharmaceutical Company Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 2.09, a 33.26% change year over year.
North China Pharmaceutical Company Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 1.57, a 10.84% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shanghai Stock Exchange: 600812.SS

North China Pharmaceutical Company Ltd.

CEO	Mr. Xin Yan Liu
IPO Date	Jan. 14, 1994
Location	China
Headquarters	No. 388, Heping East Road
Employees	10,159
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials

Description

North China Pharmaceutical Company Ltd. operates as a chemical pharmaceutical company in China. It primarily offers anti-infective drugs, comprising APIs, and intermediates and their preparations; biotechnology drugs; cardiovascular and immunomodulators; vitamins health consumer products; and bio-agricultural and veterinary drugs. North China Pharmaceutical Company Ltd. was founded in 1953 and is based in Shijiazhuang, China.

Key trends

Past 5 years